BC Innovations | May 30, 2018
Distillery Therapeutics

Infectious disease

INDICATION: Respiratory syncytial virus (RSV) Rat studies suggest vaccination during pregnancy with a vaccine based on RSV F and G proteins could help prevent RSV infection in offspring. The vaccine consists of Newcastle disease virus-like...
BC Week In Review | Nov 30, 2017
Clinical News

Bavarian Nordic reports Phase II data for MVA-BN RSV for respiratory syncytial virus

In September, Bavarian Nordic A/S (CSE:BAVA) reported data from a Phase II trial in 421 healthy volunteers aged ≥55 showing that MVA-BN RSV led to a persistent antibody response against undisclosed RSV targets at 6...
BC Innovations | Jan 3, 2017
Distillery Therapeutics

Infectious disease

INDICATION: Respiratory syncytial virus (RSV) Rat studies suggest a live attenuated RSV vaccine engineered to stably express the prefusion conformation of RSV F protein could help prevent RSV infection. The vaccine expressed an RSV F...
BC Week In Review | Dec 20, 2016
Clinical News

MVA-BN RSV: Completed Ph II enrollment

Bavarian Nordic completed enrollment of about 400 healthy volunteers ages ≥55 in a single-blind, placebo-controlled, U.S. Phase II trial evaluating 2 dose levels of MVA-BN RSV given once or twice 4 weeks apart. Bavarian Nordic...
Items per page:
1 - 4 of 4